Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$6.53 USD
-0.01 (-0.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $6.52 -0.01 (-0.15%) 6:20 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$6.53 USD
-0.01 (-0.15%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $6.52 -0.01 (-0.15%) 6:20 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
ChromaDex (CDXC) Jumps: Stock Rises 7.7%
by Zacks Equity Research
ChromaDex (CDXC) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
Abeona's Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Implied Volatility Surging for Abeona Therapeutics (ABEO) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Dynavax Technologies (DVAX) in Focus: Stock Moves 9.1% Higher
by Zacks Equity Research
Dynavax Technologies (DVAX) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
Aravive (ARAV) in Focus: Stock Moves 8% Higher
by Zacks Equity Research
Aravive (ARAV) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.
Axsome's AXS-07 Meets Co-Primary Goals in Migraine Study
by Zacks Equity Research
Axsome's (AXSM) AXS-07 achieves both regulatory co-primary endpoints in the phase III INTERCEPT study for the early treatment of migraine.
Mallinckrodt Starts Rolling BLA Filing for StrataGraft Tissue
by Zacks Equity Research
Mallinckrodt (MNK) begins rolling submission of BLA for StrataGraft regenerative skin tissue therapy to the FDA for addressing adult patients with deep partial-thickness thermal burns. Stock rises.
Is Abeona Therapeutics (ABEO) Stock a Solid Choice Right Now?
by Zacks Equity Research
Abeona Therapeutics (ABEO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Abeona Therapeutics (ABEO) Moves to Buy: Rationale Behind the Upgrade
by Zacks Equity Research
Abeona Therapeutics (ABEO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Abeona Treats First Patient in Pivotal Gene Therapy Study
by Zacks Equity Research
Abeona (ABEO) treats first patient in a pivotal study evaluating its gene-corrected cell therapy, EB-101, as a treatment for recessive dystrophic epidermolysis bullosa, a rare connective tissue disorder.
Is Earthstone (ESTE) Likely to Beat Q4 Earnings Estimates?
by Zacks Equity Research
Earthstone Energy's (ESTE) fourth-quarter earnings are likely to have been aided by higher oil production.
Factors to Know Ahead of Talos Energy's (TALO) Q4 Earnings
by Zacks Equity Research
Talos Energy's (TALO) fourth-quarter earnings are expected to have taken a hit from lower realized commodity prices.
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Onconova Therapeutics, Abeona Therapeutics, Proteostasis Therapeutics, Applied Therapeutics and Ennis
Is the Options Market Predicting a Spike in Abeona (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona (ABEO) stock based on the movements in the options market lately.
US Dollar Flexes Muscles Against Other Currencies: 5 Winners
by Tirthankar Chakraborty
The US dollar drew support from a healthy domestic economy, and Fed's cautiously optimistic stance about holding interest rates despite the coronavirus outbreak.
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Apple, Eagle Bancorp Montana, Onconova Therapeutics, Proteostasis Therapeutics and Abeona Therapeutics
Coronavirus to Hit Apple Sales: Invest in Domestic Producers
by Tirthankar Chakraborty
With the coronavirus threat increasing, it's quite evident that companies having significant exposure to China and the global economy are vulnerable. However, domestic producers of goods should remain unaffected.
Will Abeona Therapeutics Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Abeona Therapeutics.
Are Options Traders Betting On A Big Move In Abeona Therapeutics (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Are Options Traders Betting on a Big Move in Abeona Therapeutics (ABEO) Stock?
by Zacks Equity Research
Investors need to pay close attention to Abeona Therapeutics (ABEO) stock based on the movements in the options market lately.
Abeona Therapeutics (ABEO) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Abeona Therapeutics (ABEO) delivered earnings and revenue surprises of -25.64% and -100.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate Abeona Therapeutics (ABEO) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: Amgen Gets FDA Nod for Kanjinti, Regeneron Presents Data
by Zacks Equity Research
Key highlights of the past week include regulatory approvals, collaborations and pipeline updates.
Earnings Preview: Abeona Therapeutics (ABEO) Q1 Earnings Expected to Decline
by Zacks Equity Research
Abeona Therapeutics (ABEO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Abeona Therapeutics (ABEO) in Focus: Stock Moves 5.5% Higher
by Zacks Equity Research
Abeona Therapeutics (ABEO) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.